Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 29;12:9339–9349. doi: 10.2147/CMAR.S261976

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Li et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

EBLN3P regulates liver cancer cells via the miR-144-3p/DOCK4 pathway. High mRNA (A) and protein (B) expression level of DOCK4 was achieved by transfecting cells with pcDNA3.1‐DOCK4 or miR-144-3p inhibitor. Knockdown of EBLN3P markedly reduced cell proliferation (C), invasion (D and E) and migration (F). However, compared to transfection with sh-EBLN3P alone, co-transfection with sh-EBLN3P and miR-144-3p inhibitor or DOCK4 significantly increased cell proliferation (C), invasion (D and E) and migration (F). The data are shown as the mean ± SD.**P < 0.01.